Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Neogen Chemicals Ltd - 542665 - Disclosure Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations, 2015 ('Listing Regulations').

 In terms of Regulation 23(9) of the Listing Regulations, we enclose herewith the disclosure of Related Party Transactions on a consolidated basis in the format specified in the Accounting Standards for the half year ended September 30, 2022. The same is being uploaded on the Company's website www.neogenchem.com Kindly take the same on record.
08-11-2022
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 In compliance with Regulation 30 of the Listing Regulations, the audio recording of the Analysts/Investors Conference Call held on Monday, November 7, 2022, is hosted on Company''s website at https://neogenchem.com/financial-performance/
07-11-2022
Bigul

Q2FY23 Quarterly Result Announced for Neogen Chemicals Ltd.

 Specialty chemical firm Neogen Chemicals announced Q2FY23 results: Neogen Chemicals Limited (Neogen) remained on a high growth trajectory during Q2FY23 and H1FY23. The company delivered 50% growth in revenues, 35% improvement in EBITDA and a 13% increase in Profit After Tax (PAT) At Rs 296 crore, revenues registered a growth of 50% in H1FY23, over H1FY22 revenue of Rs 197.8 crore EBITDA at Rs 48.9 crore in H1FY23 was up 35% despite inflationary cost pressures in key raw materials and utilities The EBITDA percentage margin considers the impact of higher revenues and higher RM costs with preserved absolute earnings. Profit after tax (PAT) stood at Rs 21.0 crore during H1FY23 as compared to Rs 18.5 crore in H1FY22 Earnings per share (EPS) for H1FY23 stood at Rs 8.41 per share (Rs 7.94 per share in H1FY22) Commenting on the Q2 & H1 FY23 performance, Haridas Kanani, Chairman & Managing Director, Neogen Chemicals, said: “We have reported superior performance during the first half of fiscal year 2023, reflected by 50% growth in revenues, 35% improvement in EBITDA and 13% increase in Profit After Tax. This is an outcome of collective efforts put in by our teams to ensure that we expand our capabilities to the fullest and offer best possible value to our long-standing customers. The performance was fueled by continued positive demand outlook from key end-user segments, further aided by gains from incremental capacity available over same period last year. All this was achieved in an environment that was premised on prolonged inflationary headwinds in key raw materials and other utilities. Our CAPEX initiatives are underway, and construction is progressing as expected both in lithium-ion battery chemicals and existing business operations. We aim to make significant inroads in the chosen products and chemistries to elevate our performance trajectory. We have been in constant dialogue with our customers and have received positive feedback for our products. Sizeable CAPEX plans will be lined up in the second half of current fiscal year, based on how final discussion progresses for lithium-ion battery materials space. Within CSM and Advanced Intermediate space, we remain confident of garnering additional share based on our in-house strengths and capabilities across several chemistries. The objective is to diversify the product mix towards value-added offerings, and we are on the right track to attain that. The medium-to-long term prospects look favorable and Neogen is well poised to drive higher topline and profitability based on strong execution abilities. This is in addition to benefits emerging from upcoming projects that will start contributing from next year. The demand landscape remains promising and Neogen will channelise its experience to deliver sustained performance in the years to come.” Result PDF
07-11-2022
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Earnings Presentation Q2 &H1 FY 23
05-11-2022
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Press Release on the Unaudited Financial Results of the Company for the Q2 & H1 FY23.
05-11-2022
Bigul

Neogen Chemicals Ltd - 542665 - Outcome Of Board Meeting Held On Saturday, November 5, 2022

 With reference to the captioned subject and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company had at its meeting held today i.e. Saturday, November 5, 2022, inter alia considered and approved the following: Pursuant to Regulation 32 of Listing Regulations, we enclose herewith Statement of Deviation/ Variation in utilization of funds ('Statement') as at September 30, 2022, which has been duly reviewed by the Audit Committee
05-11-2022
Bigul

Neogen Chemicals Ltd - 542665 - Outcome Of Board Meeting Held On Saturday, November 5, 2022

 With reference to the captioned subject and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company had at its meeting held today i.e. Saturday, November 5, 2022, inter alia considered and approved the following: the Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended September 30, 2022, pursuant to Regulation 33 of the Listing Regulations along with the 'Limited Review Report' thereon as provided by the Statutory Auditors of the Company, which has been duly reviewed and recommended by the Audit Committee and the same is enclosed herewith;
05-11-2022
Bigul

Neogen Chemicals Ltd - 542665 - Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, November 5, 2022

 With reference to the captioned subject and in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company had at its meeting held today i.e. Saturday, November 5, 2022, inter alia considered and approved the following: 1. the Un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ended September 30, 2022, along with the 'Limited Review Report' thereon as provided by the Statutory Auditors of the Company, which has been duly reviewed and recommended by the Audit Committee and the same is enclosed herewith; 2. we enclose herewith Statement of Deviation/ Variation in utilization of funds ('Statement') as at September 30, 2022, which has been duly reviewed by the Audit Committee. The Board Meeting commenced at 3.30 p.m. and concluded at 8.15 p.m.
05-11-2022
Bigul

Neogen Chemicals Ltd - 542665 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the Listing Regulations, we would like to inform you that the Earnings Conference Call is scheduled to be held on Monday, November 7, 2022 at 4.30 p.m. IST for analysts/ investors to discuss the Q2 & FY23 results. Note: No Unpublished Price Sensitive Information will be shared during the call. We request you to please take the same on record.
01-11-2022
Bigul

Neogen Chemicals Ltd - 542665 - Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2022

 Neogen Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2022 ,inter alia, to consider and approve Pursuant to regulation 29 and 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended from time to time, notice is hereby given that a meeting of the Board of Directors of the Company is schedule to be held on Saturday, November 5, 2022, inter-alia, to consider, approve and take on record the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended on September 30, 2022. Further, as we have informed vide our letter dated September 30, 2022, the trading window closure period has commenced from Saturday, October 1, 2022 and will end 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter and half year ended on September 30, 2022 pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015.
29-10-2022
Next Page
Close

Let's Open Free Demat Account